Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial

BACKGROUND: Sintilimab blocks the interaction between programmed death-1 (PD-1) and its ligands. The safety and efficacy of sintilimab combined with oxaliplatin/capecitabine (CapeOx) as first-line treatment were evaluated in patients with gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma in...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Haiping, Zheng, Yulong, Qian, Jiong, Mao, Chenyu, Xu, Xin, Li, Ning, Xiao, Cheng, Wang, Huan, Teng, Lisong, Zhou, Hui, Wang, Shuyan, Zhu, Donglei, Peng, Bo, Shen, Lin, Xu, Nong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427727/
https://www.ncbi.nlm.nih.gov/pubmed/32795349
http://dx.doi.org/10.1186/s12885-020-07251-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427727/
https://www.ncbi.nlm.nih.gov/pubmed/32795349
http://dx.doi.org/10.1186/s12885-020-07251-z

Ejemplares similares